137 related articles for article (PubMed ID: 38686991)
1. Lipoprotein(a): an important consideration for DAPT therapy after PCI.
Cui K; Dou K
Cardiol J; 2024; 31(2):365-366. PubMed ID: 38686991
[No Abstract] [Full Text] [Related]
2. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis.
Lee OH; Kim BK; Hong SJ; Kim S; Ahn CM; Shin DH; Kim JS; Kang TS; Ko YG; Choi D; Hong MK; Jang Y
Yonsei Med J; 2020 Jul; 61(7):597-605. PubMed ID: 32608203
[TBL] [Abstract][Full Text] [Related]
3. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
[TBL] [Abstract][Full Text] [Related]
4. DAPT Shortening After Complex PCI: Examining the Fine Print.
Apostolos A; Vasilagkos G; Toutouzas K; Tsigkas G
J Am Coll Cardiol; 2023 Jun; 81(22):e191. PubMed ID: 37257958
[No Abstract] [Full Text] [Related]
5. Reply: DAPT Shortening After Complex PCI: Examining the Fine Print.
Gragnano F; Mehran R; Calabrò P; Valgimigli M;
J Am Coll Cardiol; 2023 Jun; 81(22):e193. PubMed ID: 37257959
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
[TBL] [Abstract][Full Text] [Related]
7. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
[TBL] [Abstract][Full Text] [Related]
8. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
[TBL] [Abstract][Full Text] [Related]
9. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
[TBL] [Abstract][Full Text] [Related]
10. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
[TBL] [Abstract][Full Text] [Related]
11. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention.
Malik AH; Yandrapalli S; Shetty SS; Aronow WS; Cooper HA; Panza JA
Am J Cardiol; 2020 Jul; 127():25-29. PubMed ID: 32389351
[TBL] [Abstract][Full Text] [Related]
13. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis.
Gelbenegger G; Erari-Canyurt U; Grafeneder J; Jilma B; Lesiak M; Komosa A; de Caterina R; Postula M; Siller-Matula JM
Vascul Pharmacol; 2021 Jun; 138():106858. PubMed ID: 33753284
[TBL] [Abstract][Full Text] [Related]
14. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
15. Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy.
Nardin M; Verdoia M; Gioscia R; Negro F; De Luca G
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1276-1285. PubMed ID: 33549433
[TBL] [Abstract][Full Text] [Related]
16. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
[TBL] [Abstract][Full Text] [Related]
17. Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention.
Higaki T; Kurisu S; Watanabe N; Ikenaga H; Shimonaga T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Fukuda Y; Kihara Y
Heart Vessels; 2016 Mar; 31(3):269-74. PubMed ID: 25381477
[TBL] [Abstract][Full Text] [Related]
18. Validation of the DAPT score in real-world patients undergoing coronary stent implantation.
Witberg G; Zusman O; Bental T; Plakht I; Gabbay H; Gerber Y; Kornowski R
Int J Cardiol; 2020 Feb; 300():99-105. PubMed ID: 31474410
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
[TBL] [Abstract][Full Text] [Related]
20. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
